As drug manufacturing and standards grow, pharmacopeias must adapt to meet new challenges.

As the industry continues to evolve, do we know where we're headed?

Laboratory personnel share interesting tales as well as stories of unexpected tails.

As demand for global vaccine development and production grows, all eyes are turning to Asia.

The BIO convention, and healthcare reform, could re-energize biotech.

New information improves an organization's guide to building manufacturing facilities.

Change is a part of life which some fear whilst others thrive. In the commercial world, a fundamental aspect of good management is to apply strategic insight to react to change in order to survive and grow. The pharmaceutical industry, as with every industry, is constantly exposed to new threats. Companies are all too painfully aware that the external threats that it currently faces, as well as the threat of their own drying pipelines, are forcing it to adapt and to stay on the lookout for new opportunities - now more than ever.

The US Government Accountability Office issued a report that's largely critical of FDA's efforts to fully use practices for effective strategic planning and management.

WHO Releases Draft Guideline For Production And Control Of Specified Starting Materials.

In an attempt to strengthen safeguards against counterfeit, diverted, subpotent, misbranded, adulterated, or expired drugs, FDA issued a new final guidance for industry.

Biotechnology company Genzyme reported that FDA notified the company that it intends to take enforcement action to ensure that products are made in compliance with good manufacturing practice (GMP) regulations.

Pfizer Invests In Nodality; SOCMA Approves New Members; And More.

FDA issued a final rule to make cigarettes and smokeless tobacco products less attractive and less accessible to children and adolescents.

President Obama signed into law major healthcare reform following the passage of the bill by the House of Representatives.

Seventeen pharmaceutical markets are now ranked as "pharmerging," according to market-research firm IMS Health.

FDA issued a new guidance for industry to help new drug applicants write the dosage and administration section of their products' labels.

FDA Issues Safety Warning Regarding Zocor; And More.

Merck Ends Partnership With Dynavax; PhRMA Elects Officers; And More.

After months of increasingly rancorous debate, the House finally approved legislation on Mar. 21, 2010, that makes significant changes in the nation's healthcare system.

A report from Thomson Reuters claims the number of patent challenges in the US almost doubled between 2008 and 2009.

Abbott Agrees to Acquire Facet Biotech; FDA Issues Black-Box Warning For Plavix; and More.

FDA Issues Warning Letter To Paddock Laboratories; And More.

AstraZeneca signed a license and supply agreement with the drug company and manufacturer Torrent Pharmaceuticals.

Three companies joined the University of Pittsburgh Medical Center's 21st Century Biodefense initiative to establish a flexible vaccine development and production facility.

The European Generic Medicines Association is calling for a reform of the European patent system.

In the final phase of its transparency initiative, the US Food and Drug Administration seeks additional public comments about how it can increase its interactions with regulated industry.

PharmTech's monthly newsletter, Equipment and Processing Report, reviews the Editor's Picks for the March 2010 edition from Munters and NETZSCH.

Recent developments demonstrate the importance of biologicals, which usually are delivered through injections, for the drug industry's future. To find out about the process of manufacturing prefilled syringes, and to learn about innovations in filling lines, Equipment and Processing Report talked to Thomas Otto, managing director of Vetter.